Efficacy News and Research

RSS
Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Nutranomics to distribute Nutriband transdermal delivery system in North America

Nutranomics to distribute Nutriband transdermal delivery system in North America

New center launched to increase efficacy, reduce costs at four health care providers across Indiana

New center launched to increase efficacy, reduce costs at four health care providers across Indiana

Hemianopia patients confirm prism benefits

Hemianopia patients confirm prism benefits

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

FDA Advisory Committee votes in favor of Cochlear Nucleus Hybrid L24 Implant System

FDA Advisory Committee votes in favor of Cochlear Nucleus Hybrid L24 Implant System

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Father's cocaine use may make sons less sensitive to drug and more likely to resist addictive behaviors

Father's cocaine use may make sons less sensitive to drug and more likely to resist addictive behaviors

ICS overuse warning in COPD

ICS overuse warning in COPD

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

ReShape Duo Intragastric Balloon treatment for weight loss meets primary efficacy endpoints

ReShape Duo Intragastric Balloon treatment for weight loss meets primary efficacy endpoints

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.